We found that PD-L1 expression was significantly correlated with a longer survival in these patients, indicating that the expression of PD-L1 might be a favorable prognosis biomarker for pemetrexed-based therapy, which is a rationale for combining the immunotherapy with chemotherapy for lung cancer. The gene discussed is CD274; the disease is lung carcinoma.